It is difficult to exactly date the beginning of mechanical ventilation, but there are no doubts that noninvasive ventilation (NIV) was the first method of ventilatory support in clinical practice. The technique had a sudden increase in popularity, so that it is now considered, according to criteria of evidence-based medicine, the first-line treatment for an episode of acute respiratory failure in 4 pathologies (the Fabulous Four): COPD exacerbation, cardiogenic pulmonary edema, pulmonary infiltrates in immunocompromised patients, and in the weaning of extubated COPD patients. The so-called emerging applications are those for which the evidence has not achieved level A, mainly because the number or sample size of the published studies does not allow conclusive meta-analysis. These emerging applications are the post-surgical period, palliation of dyspnea, asthma attack, obesity hypoventilation syndrome, and to prevent extubation failure. Potentially "risky business" uses include for respiratory failure from pandemic diseases and ARDS, where probably the "secret" for success is early use. Healthcare is rich in evidence-based innovations, yet even when such innovations are implemented successfully in one location, they often disseminate slowly, if at all, so their clinical use remains limited and heterogeneous. The low rate of NIV use in some hospitals relates to lack of knowledge about or experience with NIV, insufficient confidence in the technique, lack of NIV equipment, and inadequate funding. But NIV use has been increasing around the world, thanks partly to improved technologies. The skill and confidence of clinicians in NIV have improved with time and experience, but NIV is and should remain a team effort, rather than the property of a single local "champion," because, overall, NIV is beautiful!
Introduction
It is a great honor for me to give this lecture, and I thank the American Association for Respiratory Care (AARC) for giving me the opportunity. In particular I want to express my gratitude to Doug Laher, Ray Masferrer, Dean Hess, my paesano Sam Giordano, and Crystal Maldonado for the excellent organization.
Many clinicians think that mechanical ventilation started when the practice of endotracheal intubation took off. The first mentions of tracheotomy dates back to circa 3600 BC, in Egypt, but only for removal of a foreign body from the airway or to protect airways, the evidence for which was found on 2 Egyptian tablets. 1 Tracheotomy was also described in the Rig veda, an ancient Hindu text. Homerus of Byzantium is said to have written of Alexander the Great having saved a soldier from asphyxiation by making an incision with the tip of his sword in the man's trachea. 2 The Roman physician Galen may have been the first to describe mechanical ventilation: "If you take a dead animal and blow [through a reed] air through its larynx, you will fill its bronchi and watch its lungs attain the greatest distention." 2 In 1908, George Poe demonstrated his mechanical respirator by asphyxiating dogs and seemingly bringing them back to life. 2 In the early 1940s came the first reports of mechanical ventilation in humans, with oronasal mask, mainly for acute respiratory failure (ARF), which was the beginning of mechanical ventilation in clinical practice. 3 Thus, noninvasive ventilation (NIV) preceded endotracheal intubation, and for many years NIV was the preferred method of ventilation; the "iron lung" negative-pressure ventilator was the primary ventilator during the polio pandemic in the 1950s. 4 However, I would point out that NIV was first used much earlier. The book of Genesis, chapter 2:7, 5 states, "The Lord God formed man from the dust of the ground and breathed into his nostrils the breath of life, and man became a living being." What, then, is the beginning of life, if not the first use of NIV?
In the early 1980s NIV had a sudden "comeback," and the number of scientific publications increased dramatically, especially in the last decade, suggesting that NIV has become a hot topic in medicine.
Why Was NIV Slow to Take Off?
In the year 2000 an international consensus conference 6 stated that in certain conditions NIV should be considered the first-line treatment. In 2010 an international survey 7 found that about 20% of COPD patients were receiving NIV in the ICU, and that the use of NIV had dramatically increased recently in some countries, surpassing intubation as the first choice. 8 Overall in Europe, the use of NIV in the ICU is about 35% of ventilated patients and about 60% in respiratory ICUs and emergency departments. 9 In North America, NIV is most often begun in the emergency department, and most of these patients are transferred to ICUs or step-down units. 10, 11 Healthcare is rich in evidence-based innovations, yet even when such innovations are implemented successfully in one location, they often disseminate slowly, if at all. 12 Diffusion of innovations is a major challenge in all industries, including healthcare, because people react differently to novelty, following a Gaussian trend, where the majority are roughly divided into early and late innovation adopters, and the rest are "innovators" on one side and "laggards" on the other.
The low rate of NIV use in some hospitals relates to lack of knowledge about or experience with NIV, mainly among the physicians rather than for the respiratory therapists; insufficient confidence in the technique, despite the scientific evidence; lack of NIV equipment (eg, NIV ventilators and sophisticated NIV interfaces); and inadequate funding. 13 The main barrier to NIV use seems to be physiological factors rather than scientific reasons. We must, however, admit that applying and receiving NIV is not as easy as prescribing or taking a pill, so these physiological barriers may be partly justified or at least understandable.
The Fabulous Four
This year, 2012, the Beatles, also known as the Fabulous Four, are celebrated for their 50th anniversary. And for NIV we have the Fabulous Four NIV applications, based on recent randomized controlled trials (RCTs) and meta-analysis that have given NIV grade A evidence for use in respiratory failure from COPD exacerbation, cardiogenic pulmonary edema (CPE), and immunocompromised conditions, and for ventilator weaning in patients with COPD. 14 Table 1 shows the relative risks of mortality and endotracheal intubation in the studies that have compared NIV to standard treatment or conventional ventilator weaning. [15] [16] [17] [18] 
COPD Exacerbation
The first studies on the role of NIV in COPD patients experiencing acute hypercapnic respiratory failure were conducted in the early 1990s. 19, 20 Since then, several RCTs have shown that NIV added to standard medical treatment is effective in reducing mortality, avoiding intubation, improving dyspnea, and reducing hospital stay in COPD patients with ARF, compared to standard medical management plus oxygen therapy. 15, [21] [22] [23] Patients treated with NIV, irrespective of their initial illness severity, had lower rates of infectious complications (ventilator-associated pneumonia, sepsis).
An RCT with 236 subjects found that the rate of success with NIV was especially high in subjects with mild acidosis (pH Ͼ 7.30), whereas patients with more severe acidosis did not fare as well and were more likely to require intubation. 21 However, 2 RCTs comparing NIV to invasive ventilation in very acidotic patients found no differences in patient outcomes, though there were fewer complications and shorter hospital stay in one investigation, 24 and less requirement for tracheotomy and hospital admission in the following year in another study. 25 A recent prospective study 26 in the United Kingdom, with 9,716 in-patients with COPD exacerbation and ARF managed in general clinical practice, showed an overall mortality of 25% in patients receiving NIV, which is significantly higher than the figures reported in the RCTs. The study pointed to several potential explanations, including incorrect patient selection (including, in some cases, patients with mixed acidosis or prevailing metabolic acidosis), the use of NIV as a ceiling of treatment in subjects with very severe disease, and substantial delays in initiating NIV. In addition, patients with mild acidosis (in whom the effectiveness of NIV is higher) were a minority among the overall group, and they often did not receive NIV.
Cardiogenic Pulmonary Edema
CPE is a consequence of left ventricular failure and frequently leads to reduced lung compliance, with decreased functional residual capacity, regional atelectasis, ventilationperfusion mismatch, and poor gas exchange, resulting in lung failure with hypoxemic respiratory failure (P aO 2 / F IO 2 Ͻ 300 mm Hg). CPAP has long been known to improve survival and avoid intubation in CPE patients, compared to conventional treatment plus oxygen therapy. 27, 28 CPAP has the advantage of being practical and relatively easy to use; in most cases CPAP is begun in the emergency department.
In hypoxemic patients conventional NIV has not produced significant improvements over CPAP, although it can be effective in CPE patients exhibiting hypercapnia. 29, 30 However, the latter finding was recently questioned by a multicenter trial that compared oxygen therapy alone, CPAP, and NIV. 31 With NIV, the physiological improvements were faster than with oxygen alone, but there was no significant effect on the intubation or mortality rates. However, the very low intubation rate in this study (Ͻ 3%) raises questions as to whether the patient population was comparable to that of other studies. A very recent metaanalysis 16 that included this large RCT confirmed that both CPAP and NIV are more effective than standard therapy in reducing the intubation rate, and that CPAP and NIV are equally effective and without important adverse effects.
NIV for Earlier Extubation After COPD Exacerbation
The first RCT of extubation to NIV after COPD exacerbation was in severely ill COPD patients. 32 Patients who failed T-piece spontaneous breathing trial were randomized to either extubation and immediate NIV, or to continued intubation and ventilator weaning. NIV increased the likelihood of extubation success and shortened the duration of mechanical ventilation and ICU stay.
A second RCT, in patients with chronic respiratory disorders and intubated for ARF, 33 found a shorter duration of intubation in the group extubated to NIV, although no differences were found in ICU or hospital stay or 3-month survival.
In a third RCT, patients who failed spontaneous breathing trials on 3 consecutive days were randomized to either extubation and NIV, or continued intubation and a con- Unselected patients who failed T-piece spontaneous breathing trials were randomized to extubation and NIV or continued intubation and traditional weaning. The percentage of complications in the NIV group was lower, with lower incidences of pneumonia and tracheotomy. 35 More recently Girault et al 36 found that NIV for earlier extubation in difficult-to-wean patients with chronic respiratory failure did not reduce the reintubation rate within 7 days, as compared with conventional weaning and early extubation with standard oxygen therapy. Nevertheless, NIV may improve the weaning results in these patients by shortening the intubation duration and reducing the risk of post-extubation ARF.
In conclusion, the meta-analysis 18 indicates that NIV may be safely and successfully used in the ICU for earlier extubation in stable patients recovering from hypercapnic ARF and who have failed spontaneous breathing trials.
NIV for Respiratory Failure in Immunocompromised Patients
An immunocompromised status, irrespective of its specific cause, often leads to serious lung infection and severe hypoxemic respiratory failure. 37 Immunocompromised patients can benefit from NIV, especially since they are at particular risk of infectious complications related to endotracheal intubation and invasive ventilation. NIV, especially when applied early, can ameliorate their respiratory symptoms. NIV reduced the need for intubation in all the studies, 38-44 and reduced overall mortality in studies. 17, 45 Indeed, according to 2 studies, 46,47 NIV can even be administered to these patients by trained personnel outside the ICU to avoid the exposure risks in the ICU environment. These data provide a rationale for early NIV for respiratory failure in immunocompromised patients.
Emerging Applications
The so-called emerging applications are those for which the evidence is not level A, mainly because the small sample sizes in the published studies do not allow conclusive meta-analysis. 48
Prevention of Post-Surgical Complications
Major surgeries are often complicated by postoperative hypoxemia and respiratory failure, sometimes leading to death. 49 Pulmonary atelectasis after major surgery is a frequent complication and may predispose patients to pneumonia. 49 RCTs have shown that CPAP decreases atelectasis and prevents pneumonia more effectively than does standard therapy after upper abdominal surgery, 50 and that NIV significantly ameliorates gas exchange and pulmonary function abnormalities after gastrosplasty in obese patients. 51 NIV after thoracic, 52,53 cardiac, 54,55 or vascular surgeries 56 may help prevent loss of lung volume and atelectasis, while facilitating recovery. One RCT found that NIV to treat early ARF following lung resection improved survival. 57
NIV in Patients With Do-Not-Intubate Orders and for Symptom Palliation
Patients with severe irreversible disease often eschew intubation when they present with ARF, and intubation may be inappropriate if the patient is in the terminal stage. Two large United States studies on patients with ARF and do-not-intubate orders found that roughly half of the patients treated with NIV survived and were discharged from the hospital. 58, 59 The underlying disease was an important determinant of survival; patients with congestive heart failure had better survival rates than patients with COPD, and these were considerably better than those with pneumonia or cancer.
Concerning the use of NIV as a "sole" palliative measure to relieve dyspnea, 60 a recent RCT 61 found that in end-stage solid cancer patients, NIV improved dyspnea faster than did oxygen alone, and reduced the amount of morphine needed.
Asthma
Three RCTs have assessed the use of NIV during severe, non-life-threatening asthma attacks, prior to the development of ARF. The first study 62 showed improved flow and fewer hospitalizations with NIV, versus sham NIV. The second study 63 reported similar conclusions with high inflation pressure, but not with low pressure or with standard medical therapy. In patients with severe acute asthma, the addition of NIV to standard therapy probably accelerates the improvement in lung function, decreases the inhaled bronchodilator requirement, and shortens the stay in the ICU. 64 A trial of NIV can be considered to try to prevent ARF in asthmatics who fail to respond adequately to bronchodilator. Whether or not NIV is effective to treat overt ARF in asthmatics is currently unknown.
Prevention of Extubation Failure
Post-extubation respiratory failure occurs in about 15% of extubated patients, and the in-hospital mortality is approximately 30 -40%. Two RCTs have found that NIV applied immediately after extubation in patients considered to be at high risk of extubation failure lowered the reintubation rate, and in one of the studies post-extubation NIV lowered ICU mortality in a subgroup of patients with hypercapnia. 65, 66 Another RCT 67 in patients with hypercapnia at the time of extubation prospectively confirmed the latter findings, but these results were not confirmed when NIV was applied to all patients after extubation, without selecting the patients at higher risk. 68 Two other earlier RCTs tested the hypothesis that NIV could avoid reintubation in patents already showing signs of acute respiratory distress within the first 48 hours after extubation, but found no reduction in reintubation rate, 69 and one 70 even found significantly higher ICU mortality in the NIV group, associated with longer delay in reintubation. Interestingly enough, a pilot study performed in patients extubated early after hypoxic respiratory failure showed that NIV was very useful as a bridge to unsupported breathing, reducing the frequency of post-extubation failure. 71 In conclusion, although controversial, the accumulating evidence suggests that NIV has a role in treating extubation failure, but mainly in hypercapnic and congestive heart failure patients who are at high risk for extubation failure. 72 
Obesity Hypoventilation Syndrome
Obesity is an epidemic health and socioeconomic problem in many countries, and predisposes patients to chronic alveolar hypoventilation, usually in association with obstructive sleep apnea. Some case reports and observational studies [73] [74] [75] suggest that in this situation NIV can ameliorate the alveolar hypoventilation and avoid intubation, but so far RCTs are lacking.
Risky Business Pandemic Diseases
One potential application of NIV is for ARF caused by pandemic diseases such as severe acute respiratory syndrome (SARS). Based on the Toronto experience with SARS, 76 in which some clinicians contracted SARS during intubation of patients who failed NIV, the use of NIV was discouraged because of infection risk, but this was recently challenged by Simonds et al, 77 who found that the droplets generated during NIV are Ͼ 10 m, so that they are not likely to remain airborne.
As shown in Table 2 , in the investigations that have enrolled at least 40 patients receiving mechanical ventilation for ARF due to H1N1 flu, NIV was used, outside North America, as the first-line treatment in about 40% of patients. The success rate was very different between the studies, ranging from 23% to 76%, which highlights that several factors probably influenced the different patient outcomes. [78] [79] [80] [81] [82] Estenssoro et al 78 studied 337 mechanically ventilated patients with ARF due to H1N1 pneumonia. Sixty-four received NIV, and despite the relative low success rate, NIV was associated with better outcomes, possibly because the attending physicians selected NIV for the less hypoxemic patients. In all the studies the avoidance of intubation was associated with significantly fewer infectious complications, mainly sepsis and septic shock, but also catheter-related infections.
ARDS
Few clinical trials have evaluated NIV as a means to prevent intubation in patients with mild to moderate ARDS, according to the new Berlin definition (ie, P aO 2 /F IO 2 Ͼ 200 mm Hg). 83 The results have been controversial. [84] [85] [86] [87] Most of the studies enrolled patients who did not have indications that would mandate immediate endotracheal intubation under today's standard of care.
In a recent RCT 87 performed to assess the efficacy of early NIV, Zhan et al found that the proportion of patients requiring intubation was significantly lower than that in the control group (1/21 for NIV vs 7/19 for standard oxygen treatment). In more severely ill patients, Rana et al found a high failure rate and a higher than expected mortality, especially in the subgroup of patients with underlying shock, metabolic acidosis, and severe hypoxemia. 85 Antonelli et al, 88 in 3 European ICUs with NIV expertise, clarified the real-life use of NIV in ARDS patients. Only 17% of the patients admitted with ARDS were successfully treated with NIV. Over 2 years, 479 patients were admitted to the 3 ICUs, and 332 (69%) of those patients were already intubated at admission, so 147 were eligible for the study. NIV improved gas exchange and avoided intubation in 79 (54%) of those 147 patients, so the overall NIV success rate was about 20%. This was associated with less ventilator-associated pneumonia and lower ICU mortality (6% vs 53%). In summary, as an alternative to invasive ventilation in severely hypoxemic patients with ARDS (ie, P aO 2 /F IO 2 Ͻ 200 mm Hg), NIV is not generally advisable and should be limited to hemodynamically stable patients who can be closely monitored in an ICU by highly skilled staff.
Real-Life Application
As shown in Table 3 , the utilization of NIV differs greatly between hospitals and geographic regions, and has been changing. 7-9,11,89-91 A worldwide prospective survey on mechanical ventilation in ICUs found that NIV use rose from 4% of all ventilator starts in 2001 to 11% in 2004. 7 NIV is increasingly being used in many countries, but NIV use remains highly variable. It is used mainly for COPD exacerbations and CPE 89, 90, [92] [93] [94] ; use for hypoxic respiratory failure and earlier extubation is still infrequent and mainly at specialized centers. 9 In Europe the rate of NIV use in ICUs is approximately 35% of ventilated patients, and 60% in respiratory ICUs and emergency departments. 9, 94 In some places (eg, France) the use of NIV in patients initiating any form of mechanical ventilation in the ICU has surpassed intubation, irrespective of the underlying pathology. 8 A recent study performed over 10 years in the United States 91 found that in 2008 NIV surpassed intubation as the most frequently used ventilatory support in patients with COPD exacerbation. The low NIV utilization rate in some hospitals is related to lack of knowledge about or experience with NIV, insufficient NIV equipment, and lack of funding. Geographical reasons may also explain the inhomogeneous pattern of NIV utilization around the world. In Europe, for example, NIV seems to be more popular than elsewhere, perhaps because the first RCTs were performed in France and the United Kingdom. 20,21 It may be more popular there also because the physician has the direct responsibility in ordering and applying NIV with the support of all the staff, including nurses and respiratory therapists, while in most other continents the prescription is basically ordered by the physician but is independently applied by the respiratory therapist; this might affect the teamwork. In the last few years NIV use has "taken off," maybe because of improved NIV equipment, such as sophisticated ventilator algorithms able to compensate for leaks, and new NIV interfaces. 95, 96 NIV is being applied more often outside of ICUs and respiratory ICUs, including in emergency departments; post-surgical recovery rooms; cardiology, neurology, and oncology wards; and palliative care units.
Tricks and Traps
Air leak is a typical feature of NIV. Intentional leak is generated with a single-limb circuit that does not have a true expiratory valve. Leak is one of the most important factors affecting patient-ventilator synchrony. 97 When choosing the NIV interface, great consideration should be given to minimizing unintentional leak, 98 which impairs NIV efficiency, [99] [100] [101] [102] particularly during the first few hours of ventilation, when the patient is adapting to NIV, and during sleep, due to the loss of voluntary muscle control and decreased muscle tone. Interventions to reduce air leak include mask-support ring; ensuring proper interface type, size, and securing system; and optimizing patient comfort and efficiency with, for instance, hydrogel or foam seal, lip seal or mouth taping, and/or chin strap. Tightening the straps to reduce leak can decrease patient comfort and tolerance and increase the risk of skin ulcers, while not necessarily decreasing the amount of leak. 98 Unfortunately, air leak may still exist despite the above interventions. Ventilators specifically designed for NIV, as well as ICU ventilators with an NIV module, are designed to compensate for air leak, but there is high variability among such ventilators. 101, 102 The best performance, tested both in vivo and in vitro, in patient-ventilator interaction, has been with 102 When starting NIV, the clinicians should always consider that the patient needs to maintain at least a minimal respiratory capacity. We can face 2 extremes: the first is when the patient is comatose but still able to breathe by her/himself (ie, due to the effect of severe hypercapnia); the second is when the respiratory drive is abnormally increased due to anxiety and diaphoresis. Hypercapnic encephalopathy has been considered a relative contraindication to NIV because of the perceived risk of pulmonary aspiration and lack of cooperation. 14 However, several uncontrolled studies have suggested that NIV is highly successful in avoiding endotracheal intubation in patients with hypercapnic ARF and severely impaired consciousness. 103, 104 Moreover, a case-control study 105 by an experienced team found that NIV and invasive ventilation had similar short-and long-term survival, and that NIV had a lower nosocomial infection rate and a shorter duration of ventilation.
In patients with high respiratory demand, especially in the first phase of NIV application, reducing the respiratory drive is desirable, and sedative can be used, but this indication has to be balanced with the risks associated with hampering the sensorium and the patient's capacity to maintain spontaneous breathing. 106 Remifentanil is a new synthetic opioid that provides a good compromise between reducing the respiratory drive and maintaining breathing capacity, which can improve NIV tolerance. Remifentanil's advantages include a constant and short, context-sensitive plasma half-life that allows prompt recovery after stopping the infusion. Two clinical studies have suggested that a remifentanil-based sedation protocol decreased NIV intolerance. 107, 108 
And When NIV Fails? Endotracheal Intubation and New Horizons
If, despite skillful NIV application and maximal medical management, respiratory distress, gas exchange, consciousness, tachypnea, and/or acidosis worsen, then tracheal intubation becomes mandatory However, tracheal intubation and invasive ventilation have adverse effects associated with higher morbidity and mortality in COPD patients, so reducing the intubation rate should improve several outcomes. Recently, new extracorporeal CO 2 -removal devices that work at different extracorporeal blood flows have been developed 109,110 using a veno-venous system, double-lumen catheter, and CO 2 transfer membranes within a standard device for renal replacement therapy. They work with a low blood flow: Ͻ 0.5 mL/min with the 14 French catheter, or Ͼ 1 mL/min with the 18 French catheter). Preliminary studies found that this device obviated intubation in about 80% of the patients who failed NIV. If that is confirmed in an RCT, we may be able to rethink our strategy for COPD exacerbation, in 4 steps: medical therapy when ARF is not yet present; NIV for patients presenting with a pH Ͻ 7.35; extracorporeal CO 2 removal for patients who fail NIV; and intubation in the remaining patients.
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